PepLib

Zonsen PepLib Biotech Inc. is a biopharmaceutical technology enterprise dedicated to driving innovation in the global peptide new drug research and development field, with the goal of becoming a leading engine for global drug discovery. The company was founded in September 2017, with its headquarters located in Zhuzhou, China, and a subsidiary in New Jersey, USA. PepLib owns the world's first-of-its-kind Peptide Information Compression Technology (PICT), and has built an ultra-large peptide entity library containing nearly 500 million types of peptide information, as well as four complementary molecular discovery libraries: phage peptide library, animal peptide library, nanoring peptide library, and virtual peptide library. These provide a globally unique "seed bank" for peptide new drug discovery, solving the bottleneck technical challenges at the discovery stage of global peptide new drugs. Additionally, PepLib has established twelve advanced platforms, including high-throughput screening platform, virtual screening platform, structural analysis and AI discovery platform, peptide chip screening platform, peptide and small molecule drug conjugation platform, gene construction and peptide expression platform, target protein expression and cell line establishment platform, and preclinical blood-brain barrier permeability testing platform for new drugs. Based on these platforms, the company discovers novel peptide lead compounds targeting specific targets and conducts preclinical research on the identified lead compounds. To date, PepLib has completed screening for more than 50 targets, achieving a positive hit rate of over 90%, and has established more than 20 innovative drug pipelines in areas such as oncology, autoimmune diseases, and metabolic disorders. In addition, it has also laid out multiple PDC/RDC pipeline projects. PepLib will license out intellectual property rights at various preclinical stages to potential collaborators and collect licensing fees and/or milestone payments at different stages. PepLib attracts top talent and possesses strong R&D capabilities, currently employing over 20 overseas returnee leading talents. It completed a Pre-A round of financing of 100 million yuan in 2019, an A round of financing of 220 million yuan in 2021, and initiated a Pre-IPO round of financing in August 2023, with an estimated valuation of 1.55 billion yuan. Currently, PepLib has secured R&D collaboration orders from companies such as AstraZeneca, Jiudian Pharmaceutical, and Kangyuan Pharmaceutical. Adhering to the concept of innovation-driven development, PepLib will continue to introduce high-level industry professionals, invest heavily in R&D expenses, and adopt a "dual-wheel" strategy: providing new drug R&D services based on its unique and novel platforms + self-developed pipelines focusing on first-in-class innovative drug layouts. This will empower the prosperity of global peptide drugs, allowing low-cost peptide medications to benefit patients worldwide and contribute to human health.